Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07431840 · ClinicalTrials.gov registry record · NA
Immune Defense Protein Impact On Respiratory Immune Outcomes
A NA study of Influenza and Viral Upper Respiratory Infection, sponsored by Quantec.
- Recruiting
- Registry status
- NA
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT07431840: Recruiting NA study of Influenza and Viral Upper Respiratory Infection, sponsored by Quantec.
NCT07431840 is a NA study of Influenza and Viral Upper Respiratory Infection that is actively recruiting participants, run by Quantec. The registered enrollment target is 300 participants, below the 36,802-participant average among 156 other Influenza trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07431840, a NA study of Influenza and Viral Upper Respiratory Infection, is actively recruiting participants, sponsored by Quantec.
- RECRUITING
- Registry status
- NA
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary goal of this study is to observe the impact of the IDP® Supplement on the duration and severity of upper respiratory symptoms in older individuals during the cold and flu season. Secondary aims include observing the product's effect on rescue medication use, quality of life, and overall tolerability. This is conducted as a consumer-driven, decentralized observational clinical research study in adults aged 60 or older, using self-reported measures and questionnaires completed at home via the Chloe App.
Primary Outcome
To evaluate the impact of IDP® Preventative Supplementation on incidence of upper respiratory symptoms, and the duration and severity of any symptoms that occur by measuring the change in incidence of upper respiratory symptoms (frequency, type, duration and severity) between study product and placebo groups. Baseline will be compared as well.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Immune Defense Protein 50mg Dose
- DIETARY_SUPPLEMENT IDP 200mg Dose
- DIETARY_SUPPLEMENT Matching Placebo
Study Locations (1)
California
- People Science, Inc. - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-12-05 |
| Est. Completion | 2026-07-31 |
| Phase | NA |
What NCT07431840 shows while recruiting
NCT07431840 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 36,802-participant average among 156 other Influenza trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Influenza appearing as the primary indexed condition, and to 3 interventions - of which Immune Defense Protein 50mg Dose is the first listed.
NCT07431840 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07431840 about?
NCT07431840 is a clinical study titled "Immune Defense Protein Impact On Respiratory Immune Outcomes". The primary goal of this study is to observe the impact of the IDP® Supplement on the duration and severity of upper respiratory symptoms in older individuals during the cold and flu season. Secondary aims include observing the product's effect on rescue medication use, quality of life, and overall ...
What is the current status of trial NCT07431840?
This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2025-12-05. Estimated completion is 2026-07-31.
What conditions does trial NCT07431840 study?
This clinical trial studies the following conditions: Influenza, Viral Upper Respiratory Infection, Upper Respiratory Disease.
What interventions are being tested in trial NCT07431840?
The interventions under investigation include: Immune Defense Protein 50mg Dose (DIETARY_SUPPLEMENT), IDP 200mg Dose (DIETARY_SUPPLEMENT), Matching Placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07431840?
This trial is sponsored by Quantec, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07431840 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07431840's enrollment target sits among peer trials
300 67th of 156 higher than 85 of 156 other Influenza trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Influenza Immunization in Adults Over Age 75
RECRUITING · NA
-
H5N1 Milk Detection Study
RECRUITING · NA
-
Dime La VerDAD: Verify, Debunk, and Disseminate
RECRUITING · NA
-
The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program
RECRUITING · NA
-
Impact of High Dietary Fiber on Microbiome and Vaccine Responses
ACTIVE NOT RECRUITING · NA
-
Exercise and COVID-19 Viral T-cell Immunity
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI